Inventiva declares results of Phase IIb clinical trial of lanifibranor
Category: #health  By Mateen Dalal  Date: 2019-02-19
  • share
  • Twitter
  • Facebook
  • LinkedIn

Inventiva declares results of Phase IIb clinical trial of lanifibranor

The FASST clinical trial failed to meet its primary endpoint of a mean absolute change from baseline to week 48

The French clinical-stage biopharmaceutical firm Inventiva has reportedly declared the results from the ‘For A Systemic Sclerosis Treatment’ (FASST) clinical trial assessing lanifibranor for the treatment of diffuse cutaneous systemic sclerosis (dcSSc). As per trusted sources, the FASST clinical trial failed to meet its primary endpoint of a mean absolute change from baseline to week 48.

Reportedly, the FASST clinical trial included 145 patients suffering from the initial phase of dcSSc. These patients received lanifibranor in either two dosages of 600mg each day or two dosages of 400mg each day over a period of 48 weeks. Sources familiar with the matter claim that the dosages were in addition to the existing standard of care and included immunosuppressive therapy in most cases. For the record, the FASST clinical trial is a placebo-controlled, randomized, double-blind, one-year Phase IIb study.

Co-principal investigator of the FASST clinical trial and professor of rheumatology at the Hôpital Cochin in Paris, Yannick Allanore was reportedly quoted saying that the trail characterizes the first study in dcSSc with a stratified background on immunosuppressive therapy. Allanore further added that the presence of background therapy created a strong placebo effect and restricted the number of patients making progress in dcSSc.

According to a press release issued by Inventiva, over the course of the trial, the average mRSS declined in active and placebo arms with only four patients reporting to have observed increase in mRSS scores.

Co-principal investigator of the FASST clinical trial and professor at the University College of London, Christopher Denton reportedly commented that the team regrets the outcome of the study. However, lanifibranor’s favorable safety profile observed in the trial and the well-being of lanifibranor patients expressed in the global assessment has been a gratifying experience for the team.

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

Mateen has completed his Bachelor’s degree in electronics and telecommunication engineering, post which he lent his proficiency to the industry, working as a quality and test engineer. Drawn intricately toward the field of content creation however, Mateen soon switc...

Read More

More News By Mateen Dalal

Mercedes-AMG Petronas F1 Team and AMD team-up for F1 2020
Mercedes-AMG Petronas F1 Team and AMD team-up for F1 2020
By Mateen Dalal

Mercedes-AMG Petronas F1 Team, and Advanced Micro Devices (AMD), a renowned semiconductor developer, have reportedly announced a new multi-year partnership agreement that has combined the two firms’ passion of for high performance, beginning fr...

Aduro begins trial of MK-5890 for non-small cell lung cancer treatment
Aduro begins trial of MK-5890 for non-small cell lung cancer treatment
By Mateen Dalal

The biopharmaceutical giant has also received a USD 10 million development milestone payment from Merck & CO. for the initiation of the trial A clinical-stage biopharmaceutical company, Aduro Biotech, Inc. recently announced to have ba...

TherapeuticsMD submits a New Drug Application to the FDA for BIJUVA®
TherapeuticsMD submits a New Drug Application to the FDA for BIJUVA®
By Mateen Dalal

TherapeuticsMD, Inc., an inventive pharmaceutical company that focuses on women healthcare, has recently announced that it has presented a New Drug Application (NDA) pre-approval efficacy supplement to the U.S. FDA (Food and Drug Administration) for ...